Evidence map›Paper›PMID 30826992›Full record

ArticleEndocrine2019

Targeted next-generation sequencing in papillary thyroid carcinoma patients looking for germline variants predisposing to the disease.

Chen-Tian Shen, Guo-Qiang Zhang, Zhong-Ling Qiu, Hong-Jun Song, Zhen-Kui Sun, Quan-Yong Luo

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Genetic susceptibility to hereditary non-medullary thyroid cancer.Hereditary cancer in clinical practice · 2022
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Chen-Tian ShenDepartment of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 200233, Shanghai, People's Republic of China.
Guo-Qiang ZhangDepartment of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 200233, Shanghai, People's Republic of China.
Zhong-Ling QiuDepartment of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 200233, Shanghai, People's Republic of China.
Hong-Jun SongDepartment of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 200233, Shanghai, People's Republic of China.
Zhen-Kui SunDepartment of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 200233, Shanghai, People's Republic of China. sun77126@163.com.
Quan-Yong LuoDepartment of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 200233, Shanghai, People's Republic of China. lqyn@sh163.net.ORCID 0000-0003-3190-3037
Shanghai Jiao Tong University · CN

Funding

National Natural Science Foundation of China 81771865Shanghai key discipline of medical imaging 2017ZZ02005
6 · The paper itself

Abstract

purposessThe purpose of this study was using next-generation sequencing technique to explore the potential association between germline variants of 14 targeted genes and papillary thyroid carcinoma (PTC) predisposition as well as disease progression.

methodsIn all, 516 subjects were enrolled in this study including 416 PTC patients and 100 healthy controls. PTC patients were divided into distant metastasis group and non-distant metastasis group. Patients in distant metastasis group were further divided into radioiodine-refractory PTC (RR-PTC) and non-RR-PTC depending on their response to radioiodine therapy. Genomic DNA was extracted from peripheral blood sample and MiSeq Benchtop Sequencer was used for sequencing.

resultsWe found rs11246050 in NLRP6 (dominant model, OR/95% CI: 2.028/1.091-3.769, p = 0.025), rs2286742 and rs3740530 in HABP2 (recessive model, OR/95% CI: 9.644/1.307-71.16, p = 0.026 and 3.989/1.413-11.26, p = 0.009), rs2736098 in TERT (recessive model, OR/95% CI: 2.322/1.028-5.242. p = 0.042) and rs62054619 in GAS8-AS1 (recessive model, OR/95% CI: 2.219/1.067-4.617, p = 0.033) were associated with the risk of PTC. rs1137282 in KRAS (dominant model, OR/95% CI: 0.5430/0.3192-0.9236, p = 0.024), rs1347591 and rs4461062 in NUP93 (dominant model, OR/95% CI: 0.6121/0.4128-0.9076, p = 0.015 and 0.6156/0.4157-0.9117, p = 0.015) were associated with low risk of distant metastatic disease in PTC patients. rs33954691 in TERT was associated with the risk of RR-PTC under dominant model (OR/95% CI: 3.161/1.596-6.262).

conclusionsGermline variants of related genes could be associated with the susceptibility of PTC as well as disease progression (distant metastasis and radioiodine-refractory status). However, these results must be further verified and the potential biological functions of these germline variants in the pathogenesis of PTC remain to be determined in future studies.

Indexed as

Genetic Predisposition to DiseaseGerm-Line MutationAdolescentAdultAgedAged, 80 and overChildDisease ProgressionFemaleGenotypeHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedPolymorphism, Single NucleotideThyroid Cancer, PapillaryMetastasisNext-generation sequencingPapillary thyroid carcinomaRadioiodine-refractory PTC

Identifiers

PMID30826992
OpenAlexW2919498027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.